Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals

J. C. Lima-Junior, T. M. Tran, E. V.S. Meyer, B. Singh, S. G. De-Simone, F. Santos, C. T. Daniel-Ribeiro, A. Moreno, J. W. Barnwell, M. R. Galinski, J. Oliveira-Ferreira

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Antibody and T-cell reactivities to Plasmodium vivax merozoite surface protein 9 (PvMSP9) were evaluated in a cross-sectional study of individuals naturally exposed to malaria infections living in Ribeirinha, a native riverine community and in Colina, a transmigrant community, Rondonia, Brazil. The antibody responses to PvMSP9-RIRII and PvMSP9-Nt domains in Ribeirinha were higher compared with Colina and correlated with age and time of malaria exposure. IgG2 was most prevalent for PvMSP9-RII in both communities, and IgG1 was the predominant isotype for PvMSP9-Nt and PvMSP9-RIRII in Ribeirinha. IFN-γ and IL-4 predominated in Ribeirinha, while IFN-γ predominated in Colina. Variation in exposure to P. vivax likely accounts for the differences observed in cytokine and antibody levels between the two populations studied.

Original languageEnglish (US)
Pages (from-to)6645-6654
Number of pages10
JournalVaccine
Volume26
Issue number51
DOIs
StatePublished - Dec 2 2008

    Fingerprint

Keywords

  • Malaria
  • Merozoite surface protein 9
  • Plasmodium vivax
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Lima-Junior, J. C., Tran, T. M., Meyer, E. V. S., Singh, B., De-Simone, S. G., Santos, F., Daniel-Ribeiro, C. T., Moreno, A., Barnwell, J. W., Galinski, M. R., & Oliveira-Ferreira, J. (2008). Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine, 26(51), 6645-6654. https://doi.org/10.1016/j.vaccine.2008.09.029